NCT00363753

Brief Summary

Pilot study of continuing aspirin versus switching to clopidogrel after stroke or transient ischemic attack.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Aug 2006

Shorter than P25 for phase_1

Geographic Reach
1 country

2 active sites

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2006

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

August 10, 2006

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 15, 2006

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2007

Completed
Last Updated

August 2, 2019

Status Verified

July 1, 2019

First QC Date

August 10, 2006

Last Update Submit

July 31, 2019

Conditions

Transient Ischemic AttackStrokeAspirinClopidogrel

Keywords

Transient ischemic attackStrokeAspirinClopidogrel

Outcome Measures

Primary Outcomes (1)

  • mRS at three months.

Secondary Outcomes (1)

  • Incidence of stroke at three months, bleeding events.

Interventions

aspirin versus clopidogrelDRUG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 and older.
  • Stroke or transient ischemic attack (TIA) while taking aspirin within one week of consent.
  • Women of child-bearing potential will be included only if there is a negative pregnancy test and they agree to birth control during the treatment period.

You may not qualify if:

  • Any medical indication for a specific antiplatelet agent (aspirin, clopidogrel, ticlopidine, aggrenox), or an indication for a combination of antiplatelet agents.
  • Any medical indication for anticoagulation, except subcutaneous heparin for deep vein thrombosis prophylaxis.
  • Allergy to aspirin or clopidogrel.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

UCSD Hillcrest

San Diego, California, 92103, United States

Location

UCSD

San Diego, California, 92103, United States

Location

MeSH Terms

Conditions

Ischemic Attack, TransientStroke

Condition Hierarchy (Ancestors)

Brain IschemiaCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Matt B Jensen, MD

    UCSD Stroke Center

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

August 10, 2006

First Posted

August 15, 2006

Study Start

August 1, 2006

Study Completion

March 1, 2007

Last Updated

August 2, 2019

Record last verified: 2019-07

Locations

US(2)